Trial Profile
Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Lenadogene nolparvovec (Primary)
- Indications Leber's hereditary optic atrophy
- Focus Adverse reactions
- Acronyms RESTORE
- Sponsors GenSight Biologics
- 27 Apr 2023 Results from REVERSE, RESCUE, RESTORE and REFLECT; comparing visual acuity of Leber hereditary optic neuropathy (LHON) patients treated with lenadogene nolparvovec, presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 27 Apr 2023 Results(n=62) assessing assess the long-term safety and efficacy of lenadogene nolparvovec gene therapy in patients with Leber hereditary optic neuropathy presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 10 Mar 2023 According to a GenSight Biologics media release, data from this trial will be presented at the North American Neuro Ophthalmology Society (NANOS) 49th Annual Meeting, The American Academy of Neurology (AAN) Annual Meeting and The Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting 2023.